UP!

ALKS $16.74   View long term graphs

Alkermes plc
Type
Public NASDAQ: ALKS
Industry Biotechnology
Headquarters Dublin, Ireland
Key people
Richard Pops, CEO
Revenue Increase US$187 Million
Operating income
Decrease US$-42.9 Million
Net income
Decrease US$-39.6 Million
Total assets Decrease US$452 Million
Total equity Decrease US$392 Million
Number of employees
1200
Website www.alkermes.com

Alkermes plc is a biopharmaceutical company that focuses on central nervous system (CNS) diseases. The company is the result of a merger in September 2011 between Alkermes, Inc., and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.

Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases, such as addiction, schizophrenia, diabetes and depression. Among these products, five are primary to the company: risperidone long-acting Injection (generic for Risperdal Consta) for schizophrenia and bipolar 1 disorder, paliperidone palmitate (generic for Invega Sustenna in the U.S., Xeplion in Europe) for schizophrenia, 4-aminopyridine (generic for Ampyra in the U.S., Fampyra in Europe) to improve walking in patients with multiple sclerosis, naltrexone for extended-release injectable suspension (generic for Vivitrol) for alcohol and opioid dependence, and exenatide extended-release for injectable suspension (generic for Bydureon) for the treatment of type 2 diabetes. Bydureon is a once-weekly, extended-release form of the drug, exenatide (Byetta), and was developed through a partnership between Amylin Pharmaceuticals, Alkermes and Eli Lilly. It is approved in Europe and the U.S.

Buprenorphine/samidorphan (ALKS-5461), a κ-opioid receptor antagonist, is a next-generation, novel antidepressant which is under development by Alkermes for treatment-resistant depression.

Olanzapine/samidorphan (ALKS-3831) is an atypical antipsychotic and opioid modulator combination that is under development for the treatment of schizophrenia and bipolar mania.

News

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-10 Future report Set alerts
Q3 2020 2020-10-21 Future report Set alerts
Q2 2020 2020-07-29 0.06 -0.19
Q1 2020 2020-04-29 0.01 -0.24
Q4 2019 2020-02-13 0.83 -0.03
Q3 2019 2019-10-23 -0.04 -0.34
Q2 2019 2019-07-25 0.09 -0.27
Q1 2019 2019-04-25 -0.17 -0.62
Q4 2018 2019-02-14 0.34 -0.06
Q3 2018 2018-10-23 0.07 -0.22

Ratings

2016-06-28 Reiterated Rating Leerink Swann Outperform $58.00 to $54.00
2016-06-02 Reiterated Rating Jefferies Group Buy
2016-06-02 Reiterated Rating Credit Suisse Buy
2016-06-02 Reiterated Rating Credit Suisse Group AG Buy
2016-05-26 Initiated Coverage Evercore ISI Buy $59.00
2016-05-25 Reiterated Rating Leerink Swann Outperform $58.00
2016-05-05 Initiated Coverage Cowen and Company Market Perform
2016-04-30 Reiterated Rating Morgan Stanley Sell
2016-04-21 Reiterated Rating Leerink Swann Buy
2016-03-07 Reiterated Rating Credit Suisse Buy
2016-02-27 Reiterated Rating Jefferies Group Buy
2016-02-22 Lower Price Target Goldman Sachs $57.00 to $35.00
2016-02-22 Lower Price Target Goldman Sachs Group Inc. $57.00 to $35.00
2016-02-16 Reiterated Rating Leerink Swann Outperform $58.00
2016-02-08 Lower Price Target Citigroup Inc. Neutral $36.00
2016-01-22 Reiterated Rating Leerink Swann Buy
2016-01-21 Reiterated Rating Guggenheim Hold
2016-01-21 Reiterated Rating Jefferies Group Buy
2016-01-21 Downgrade JPMorgan Chase & Co. Overweight to Neutral $77.00 to $51.00
2016-01-21 Downgrade Morgan Stanley Overweight to Underweight $35.00
2016-01-21 Downgrade Cowen and Company Outperform to Hold $80.00 to $50.00
2016-01-21 Lower Price Target Leerink Swann Outperform $84.00 to $58.00
2016-01-13 Reiterated Rating JPMorgan Chase & Co. Overweight
2015-12-03 Reiterated Rating Credit Suisse Outperform $67.00 to $80.00
2015-11-06 Boost Price Target Leerink Swann Outperform $81.00 to $84.00
2015-10-30 Boost Price Target Jefferies Group $76.00 to $81.00
2015-10-30 Reiterated Rating Barclays Buy $79.00 to $83.00
2015-10-30 Reiterated Rating Barclays PLC Buy $79.00 to $83.00
2015-10-29 Reiterated Rating JPMorgan Chase & Co. Buy $77.00
2015-10-29 Reiterated Rating Leerink Swann Outperform
2015-10-07 Boost Price Target Barclays Overweight $77.00 to $79.00
2015-10-06 Reiterated Rating Credit Suisse Buy
2015-10-06 Reiterated Rating Morgan Stanley Buy
2015-09-01 Upgrade Morgan Stanley Underweight to Overweight $61.00 to $85.00
2015-07-30 Reiterated Rating JPMorgan Chase & Co. Buy $77.00
2015-07-29 Reiterated Rating Cowen and Company Buy $80.00
2015-07-20 Boost Price Target Goldman Sachs Neutral $47.00 to $48.00
2015-06-09 Initiated Coverage Guggenheim Neutral
2015-05-21 Initiated Coverage Barclays Overweight $74.00
2015-05-20 Initiated Coverage Credit Suisse Outperform
2015-05-12 Initiated Coverage Credit Suisse Outperform $75.00 to $59.51
2015-05-09 Reiterated Rating Jefferies Group Buy $78.00 to $74.00
2015-05-01 Reiterated Rating JPMorgan Chase & Co. Overweight $77.00
2015-03-27 Downgrade Citigroup Inc. Buy to Neutral $83.00 to $71.00
2015-03-12 Downgrade Morgan Stanley Equal Weight to Underweight $61.00
2015-03-10 Lower Price Target Jefferies Group Buy $80.00 to $78.00
2015-02-25 Lower Price Target Citigroup Inc. Buy $85.00 to $83.00
2015-02-25 Set Price Target Bank of America Sell $45.00
2015-02-25 Set Price Target Bank of America Corp. Sell $45.00
2015-02-24 Reiterated Rating JPMorgan Chase & Co. Overweight $77.00
2015-02-09 Reiterated Rating JPMorgan Chase & Co. Buy
2015-01-14 Boost Price Target Citigroup Inc. Buy $72.00 to $85.00
2015-01-08 Boost Price Target Leerink Swann Outperform $66.00 to $75.00
2015-01-08 Boost Price Target Mizuho Buy $72.00 to $81.00
2015-01-06 Reiterated Rating JPMorgan Chase & Co. Buy
2014-12-17 Reiterated Rating Citigroup Inc. Buy $60.00 to $72.00
2014-12-08 Boost Price Target Credit Suisse Outperform $56.00 to $63.00
2014-08-01 Lower Price Target Credit Suisse $57.00 to $56.00
2014-07-31 Lower Price Target Mizuho Buy $61.00 to $59.00
2014-05-16 Initiated Coverage Jefferies Group Buy $53.00
2014-04-10 Upgrade Mizuho Neutral to Buy $56.00 to $61.00
2014-04-09 Boost Price Target MKM Partners Sell $32.00 to $35.00
2014-04-08 Reiterated Rating Leerink Swann Outperform $60.00 to $66.00
2014-04-02 Initiated Coverage Credit Suisse Outperform $57.00
2014-02-28 Reiterated UBS Neutral $42 to $53
2014-02-28 Boost Price Target MKM Partners Sell $26.00 to $32.00
2014-02-28 Boost Price Target Mizuho Neutral $33.00 to $56.00
2014-01-24 Boost Price Target Leerink Swann $46.00 to $58.00
2013-12-16 Boost Price Target Leerink Swann $42.00 to $46.00
2013-12-05 Downgrade UBS Buy to Neutral $37 to $42
2013-11-01 Boost Price Target Mizuho Neutral $30.00 to $33.00
2013-10-30 Initiated Coverage FBR & Co. Market Perform $31.00
2013-10-17 Reiterated Rating Citigroup Inc. Focus List $38.00 to $43.00
2013-10-01 Downgrade Morgan Stanley Overweight to Equal Weight
2013-05-24 Reiterated UBS Buy $32 to $37
2013-05-24 Downgrade MKM Partners Neutral to Sell
2013-04-18 Downgrade Mizuho Buy to Neutral $30 to $26
2013-04-17 Reiterated MKM Partners Neutral $23 to $25
2013-01-23 Downgrade MKM Partners Buy to Neutral
2012-11-16 Initiated Mizuho Buy $27
2012-01-25 Upgrade MKM Partners Neutral to Buy $19 to $20
2011-08-23 Upgrade UBS Neutral to Buy $20.50 to $21
2011-07-08 Reiterated UBS Neutral $19 to $20.50
2011-06-07 Reiterated UBS Neutral $16.50 to $19
2011-05-10 Reiterated UBS Neutral $14.50 to $16.50
2010-10-20 Downgrade Caris & Company Above Average to Average $16 to $10
2016-06-28 Reiterated Rating Leerink Swann Outperform $58.00 to $54.00
2016-06-02 Reiterated Rating Jefferies Group Buy
2016-06-02 Reiterated Rating Credit Suisse Buy
2016-06-02 Reiterated Rating Credit Suisse Group AG Buy
2016-05-26 Initiated Coverage Evercore ISI Buy $59.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
POPS RICHARD F Director and CEO, Alkermes plc 0.46%  (666352) ALKS / EPZM / NBIX / XLRN /
LANDINE MICHAEL J SVP, Corp Dev., Alkermes, Inc. 0.12%  (172644) ALKS / KOPN /
Cooke Shane President, Alkermes plc 0.06%  (84872) ALKS / PRTA /
FRATES JAMES M SVP & CFO, Alkermes plc 0.06%  (84340) ALKS / SAGE /
Ehrich Elliot SVP, R&D & CMO, Alkermes, Inc. 0.04%  (57056) ALKS /
ANSTICE DAVID W 0.04%  (55000) ALKS /
Stejbach Mark Chief Commercial Officer 0.04%  (51065) ALKS / FLXN / TNGN /
BIBERSTEIN KATHRYN L SVP, GC, Secretary, Alks, Inc. 0.03%  (40200) ALKS /
Gaffin David Joseph SVP, CLO, Alkermes, Inc. 0.02%  (36363) ALKS /
Brown Iain Michael VP, Finance & CAO 0.02%  (21895) ALKS /
Pugh Gordon G SVP, COO & CRO, Alkermes, Inc. 0.01%  (20587) ALKS /
BLOOM FLOYD E 0.01%  (20000) ALKS /

Comments